Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
1995-06-07
2002-08-20
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S184100, C424S204100, C435S235100, C530S350000, C530S403000
Reexamination Certificate
active
06436403
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to functional domains and fragments of the intercellular adhesion molecule, ICAM-1. Such functional domains and fragments may be used in the treatment of viral, and particularly rhinoviral disease.
2. Description of the Related Art
I. The Intercellular Adhesion Molecule ICAM-1 and Cellular Adhesion
The intercellular adhesion molecule ICAM-1 was first identified and partially characterized according to the procedure of Rothlein, R. et al. (
J. Immunol.
137:1270-1274 (1986)), which reference is herein incorporated by reference. ICAM-1, its preparation, purification, and characteristics are disclosed in U.S. patent application Ser. Nos. 07/045,963 (filed on May 4, 1987), 07/115,798 (filed on Nov. 2, 1987), 07/155,943 (filed on Feb. 16, 1988), 07/189,815 (filed on May 3, 1988) and 07/250,446 (filed on Sep. 28, 1988), all of which applications are herein incorporated by reference in their entirety.
ICAM-1 was initially realized as being involved in the process of cellular adhesion between endothelial cells and leukocytes. Cellular adhesion is the process through which leukocytes attach to cellular substrates, such as endothelial cells, in order to migrate from circulation to sites of ongoing inflammation, and properly defend the host against foreign invaders such as bacteria or viruses. An excellent review of the defense system is provided by Eisen, H. W., (In:
Microbiology,
3rd Ed., Harper & Row, Philadelphia, Pa. (1980), pp. 290-295 and 381-418).
One of the molecules on the surface of endothelial cells which participates in the adhesion process is ICAM-1. This molecule has been shown to mediate adhesion by binding to molecules of the CO-18 family of glycoproteins which are present on the cell surfaces of leukocytes (Sanchez-Madrid, F. et al.,
J. Exper. Med.
158:1785-1803 (1983); Keizer, G. D. et al.,
Eur. J. Immunol.
15:1142-1147 (1985)). This glycoprotein family is composed of heterodimers having one alpha chain and one beta chain. Although the alpha chain of each of the antigens differed from one another, the beta chain was found to be highly conserved (Sanchez-Madrid, F. et al.,
J. Exper. Med.
158:1785-1803 (1983)). The beta chain of the glycoprotein family (sometimes referred to as “CD18”) was found to have a molecular weight of 95 kd whereas the alpha chains were found to vary from 150 kd to 180 kd (Springer, T.,
Fed. Proc.
44:2660-2663 (1985)). Although the alpha subunits of the membrane proteins do not share the extensive homology shared by the beta subunits, close analysis of the alpha subunits of the glycoproteins has revealed that there are substantial similarities between them. There are three major members of the CD-18 family: p150,95, MAC-1 and LFA-1. Mac-1 is a heterodimer found on macrophages, granulocytes and large granular lymphocytes. LFA-1 is a heterodimer found on most lymphocytes (Springer, T. A., et al.
Immunol. Rev.
68:111-135 (1982)). P150,95 has a tissue distribution similar to Mac-1, and also plays a role in cellular adhesion (Keizer, G. et al.,
Eur. J. Immunol.
15:1142-1147 (1985)). Reviews of the similarities between the alpha and beta subunits of the LFA-1 related glycoproteins are provided by Sanchez-Madrid, F. et al., (
J. Exper. Med.
158:586-602 (1983);
J. Exper. Med.
158:1785-1803 (1983)).
II. The Cellular Receptor for Human Rhinovirus
Abraham et al. (
J. Virol.
51:340-345 (1984)) discovered that the majority of randomly selected human rhinovirus (“HRV”) serotypes were able to bind to the same cellular receptor. A monoclonal antibody was subsequently developed by Colonno et al. (Colonno et al.,
J. Cell. Biochem. Suppl.
10 (part D):266 (1986); Colonno et al.,
J. Virol.
57:7-12 (1986); Colonno et al., European Patent Application Publication No. 169,146) which was capable of blocking attachment of HRV of the major serotype to the surfaces of endothelial cells. The endothelial cell receptor protein recognized by this antibody was isolated and found to be a 90 kd protein (Tomassini et al.,
J. Virol.
58:290-295 (1986).
SUMMARY OF THE INVENTION
The present invention relates to the use of functional derivatives of Intercellular Adhesion Molecule-1 (ICAM-1) in anti-viral therapy. Of particular concern to the invention are those functional derivatives of ICAM-1 which comprises fragments of the intact ICAM-1 molecule.
In detail, the invention provides a method for treating viral infection in an individual in need of such treatment, wherein the method comprises providing to the individual an amount of a fragment of ICAM-1 or a fragment of a functional derivative of ICAM-1 sufficient to suppress viral infection.
The invention further provides a method of diagnosing the presence of viral infection, the method comprising:
(a) incubating a biological sample suspected of containing a virus with a detectably labeled ICAM-1 functional derivative;
(b) determining whether any of the detectably labeled ICAM-1 functional derivative has become bound to virus.
The invention further provides a method of preventing viral infection which comprises providing to a recipient a vaccine composition, the composition containing a virus bound to a functional derivative of ICAM-1.
REFERENCES:
patent: 4946676 (1990-08-01), Van Wezel et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5235049 (1993-08-01), McClelland et al.
patent: 5288854 (1994-02-01), Diamond et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5475091 (1995-12-01), Springer et al.
patent: 5589453 (1996-12-01), Greve
patent: 5612216 (1997-03-01), Springer et al.
patent: 5674982 (1997-10-01), Greve et al.
patent: 0169146 (1986-01-01), None
patent: 0 289 949 (1988-11-01), None
patent: 0 319 815 (1989-06-01), None
patent: 0 379 904 (1990-08-01), None
Kogan et al. J Biol Chem 270: 14047-14055, (1995).*
Rozdzinski et al. J. Infert Diseases 168: 1422-1428, (1993).*
Ngo et al. In the Protein Folding Problem and Tertiary Structure Prediction, Ed. Merz et al. Birkhauser Boston 1994, pp. 491-495.*
Tomassini, J., “Isolation, characterization, and cloning of the cellular receptor for the major group of human rhinoviruses,”Dissertation Abstracts International, B.47:2774-B (1987).
White, J.M. & Littman, D.R., “Viral Receptors of the Immunoglobulin Superfamily,”Cell 56:725-729 (1989).
Abraham, G., et al., “Many Rhinovirus Serotypes Share the Same Cellular Receptor,”J. Virol.51(2):340-345 (1984).
Arruda, E., et al., “In Vitro Studies of the Antirhinovirus Activity of Soluble Intercellular Adhesion Molecule-1,”Antimicrob. Agents and Chemother.36(6):1186-1191 (1992).
Colonno, R. J., et al., “Isolation of a Monoclonal Antibody that Blocks Attachment of the Major Group of Human Rhinoviruses,”J. Virol.57 (1):7-12 (1986).
Colonno, R. J., et al., “Human Rhinovirus Attachment Requires a Specific Cellular Receptor Protein,”J. Cell. Biochem. Suppl 10(part D) :266 (1986).
Couch, R. B., “Rhinoviruses,” in:Virology,Fields, B. N., et al., eds., New York: Raven Press, pp. 607-629 (1990).
Crump, C. E., et al., “In vitro Inhibitory Activity of Soluble ICAM-1 for the Numbered Serotypes of Human Rhinovirus,”Antivir. Chem. and Chemother.4(6): 323-327 (1993).
Dustin, M. L., et al., “Induction by Il-1 and Interferon-y: Tissue Distribution, Biochemistry, and Function of a Natural Adherence Molecule (ICAM-1),”J. Immun.137(1):245-254 (1986).
Greve, J. M., et al., “The Major Human Rhinovirus Receptor is ICAM-1,”Cell 56:839-847 (1989).
Hayden, F. G., et al., “Modification of Experimental Rhinovirus Colds by Receptor Blockade,”Antivir. Res.9:233-247 (1988).
Keizer, G. D., et al., “Biochemical and Functional Characteristics of the Human Leukocyte Membrane Antigen Family LFA-1, Mo-1 and p150,95,”Eur. J. Immunol.15:1142-1147 (1985).
Martin, S., et al., “Functional Studies of Truncated Soluble Intercellular Adhesion Molecule 1 Expressed inEscherichia coli,”Antimicrob. Agents and Chemother.37(6):1278-1285 (1993).
Olson, N. H., et al., “Structure of Human Rhinovirus Complexed with its Receptor Molecule,”Proc. Natl. Acad. Sci. USA 90:507-511 (199
Springer Timothy A.
Staunton Donald E.
Center for Blood Research, Inc.
Gambel Phillip
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Pharmaceutical composition of the intercellular adhesion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition of the intercellular adhesion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition of the intercellular adhesion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2903975